Johnson & Johnson (JNJ) Total Debt (2009 - 2026)

Johnson & Johnson's (JNJ) quarterly Total Debt came in at $55.0 billion in Q1 2026, up 5.23% year-on-year from $52.3 billion in Q1 2025, and up 14.72% quarter-over-quarter from $47.9 billion in Q4 2025.

Johnson & Johnson (JNJ) Total Debt (2009 - 2026) Analysis & Trends

Johnson & Johnson has disclosed Total Debt across 18 years of filings, most recently posting $55.0 billion for Q1 2026.

  • Total Debt for Q1 2026 came in at $55.0 billion, up 5.23% year-over-year; the trailing twelve-month figure through Mar 2026 was $55.0 billion (up 5.23% YoY), and the FY2025 annual result was $47.9 billion, up 30.84% from the prior year.
  • Total Debt came in at $55.0 billion for Q1 2026 at Johnson & Johnson, up from $47.9 billion in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $55.0 billion in Q1 2026 to a low of $29.3 billion in Q4 2023.
  • The 5-year median for Total Debt is $38.1 billion (2023), against an average of $40.5 billion.
  • Across the five-year window, Total Debt surged 59.61% in 2023 and slumped 36.43% in 2024, its largest moves.
  • Johnson & Johnson's Total Debt stood at $32.0 billion in 2022, then slipped by 8.41% to $29.3 billion in 2023, then rose by 24.89% to $36.6 billion in 2024, then soared by 30.84% to $47.9 billion in 2025, then increased by 14.72% to $55.0 billion in 2026.
  • The last three Total Debt figures came in at $55.0 billion (Q1 2026), $47.9 billion (Q4 2025), and $45.8 billion (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Gsk 96,436,181.12 Bn 96,436,176.16 Bn 7.76 Bn -18.89 Bn
2 Eli Lilly 1,017.30 Bn 1,012.01 Bn 16.22 Bn 43.37 Bn
3 Johnson & Johnson 579.61 Bn 557.55 Bn 15.96 Bn 54.99 Bn
4 AbbVie 402.30 Bn 392.96 Bn 10.78 Bn 64.53 Bn
5 Merck 294.24 Bn 288.59 Bn 12.09 Bn 49.12 Bn
6 Amgen 191.82 Bn 179.78 Bn 5.87 Bn 57.32 Bn
7 Gilead Sciences 155.93 Bn 148.21 Bn 5.52 Bn 22.17 Bn
8 Pfizer 149.05 Bn 136.28 Bn -1.21 Bn 64.46 Bn
9 Bristol Myers Squibb 116.33 Bn 105.88 Bn 8.07 Bn 44.46 Bn
10 Novartis Ag 112.59 Bn 111.90 Bn - -

Historic Data

Download Data
DateValue
Mar 29, 2026 54.99 Bn
Dec 28, 2025 47.93 Bn
Sep 28, 2025 45.80 Bn
Jun 29, 2025 50.76 Bn
Mar 30, 2025 52.25 Bn
Dec 29, 2024 36.63 Bn
Sep 29, 2024 35.75 Bn
Jun 30, 2024 41.49 Bn
Mar 31, 2024 33.63 Bn
Dec 31, 2023 29.33 Bn
Oct 1, 2023 29.92 Bn
Jul 2, 2023 45.60 Bn
Apr 2, 2023 52.91 Bn
Jan 1, 2023 39.64 Bn
Oct 2, 2022 32.03 Bn
Jul 3, 2022 32.60 Bn
Apr 3, 2022 33.15 Bn
Jan 2, 2022 33.75 Bn
Oct 3, 2021 33.93 Bn
Jul 4, 2021 33.48 Bn